Group 1 - The first overseas price certificate in China was issued to a Beijing-based innovative pharmaceutical company, allowing its original drug for treating infantile hemangioma to enter international markets more rapidly [1] - The drug addresses a significant clinical gap in treating a common benign tumor in infants, with a global incidence rate of approximately 5% to 12%, indicating substantial overseas market demand [1] - The company is a small and micro enterprise, highlighting the importance of such firms in China's pharmaceutical innovation landscape [1] Group 2 - The China Drug Price Registration System was launched on December 2, 2025, adopting a service model of "one location acceptance, nationwide sharing, global openness" [2] - The system allows companies to independently declare drug prices, which are considered real and reasonable market prices outside of domestic medical insurance settlements, without affecting drug prices for insured and uninsured populations [2] - The system also provides services such as price registration, inquiry, and multilingual certification, with a physical service window established in Beijing [2]